HRP20150138T1 - Supstituirane soli 2,3-dihidroimidazo[1,2-c]kinazolina - Google Patents

Supstituirane soli 2,3-dihidroimidazo[1,2-c]kinazolina Download PDF

Info

Publication number
HRP20150138T1
HRP20150138T1 HRP20150138TT HRP20150138T HRP20150138T1 HR P20150138 T1 HRP20150138 T1 HR P20150138T1 HR P20150138T T HRP20150138T T HR P20150138TT HR P20150138 T HRP20150138 T HR P20150138T HR P20150138 T1 HRP20150138 T1 HR P20150138T1
Authority
HR
Croatia
Prior art keywords
mixture
dihydrochloride salt
salt according
hours
temperature
Prior art date
Application number
HRP20150138TT
Other languages
English (en)
Croatian (hr)
Inventor
Jan Georg Peters
Hans-Christian Militzer
Hartwig Müller
Original Assignee
Bayer Intellectual Property Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43984137&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20150138(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Intellectual Property Gmbh filed Critical Bayer Intellectual Property Gmbh
Publication of HRP20150138T1 publication Critical patent/HRP20150138T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20150138TT 2011-04-05 2012-03-29 Supstituirane soli 2,3-dihidroimidazo[1,2-c]kinazolina HRP20150138T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11161111A EP2508525A1 (en) 2011-04-05 2011-04-05 Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
PCT/EP2012/055600 WO2012136553A1 (en) 2011-04-05 2012-03-29 Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
EP12712104.4A EP2694508B1 (en) 2011-04-05 2012-03-29 Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts

Publications (1)

Publication Number Publication Date
HRP20150138T1 true HRP20150138T1 (hr) 2015-05-08

Family

ID=43984137

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20150138TT HRP20150138T1 (hr) 2011-04-05 2012-03-29 Supstituirane soli 2,3-dihidroimidazo[1,2-c]kinazolina

Country Status (42)

Country Link
US (2) US10383876B2 (cg-RX-API-DMAC7.html)
EP (2) EP2508525A1 (cg-RX-API-DMAC7.html)
JP (2) JP5763834B2 (cg-RX-API-DMAC7.html)
KR (1) KR101937501B1 (cg-RX-API-DMAC7.html)
CN (1) CN103649091B (cg-RX-API-DMAC7.html)
AP (1) AP3709A (cg-RX-API-DMAC7.html)
AR (1) AR085718A1 (cg-RX-API-DMAC7.html)
AU (1) AU2012238891B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013025549A2 (cg-RX-API-DMAC7.html)
CA (1) CA2832123C (cg-RX-API-DMAC7.html)
CL (1) CL2013002870A1 (cg-RX-API-DMAC7.html)
CO (1) CO6781534A2 (cg-RX-API-DMAC7.html)
CR (1) CR20130511A (cg-RX-API-DMAC7.html)
CU (1) CU24208B1 (cg-RX-API-DMAC7.html)
CY (1) CY1116231T1 (cg-RX-API-DMAC7.html)
DK (1) DK2694508T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2013000223A (cg-RX-API-DMAC7.html)
EA (1) EA023646B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP13013006A (cg-RX-API-DMAC7.html)
ES (1) ES2529653T3 (cg-RX-API-DMAC7.html)
GT (1) GT201300234A (cg-RX-API-DMAC7.html)
HR (1) HRP20150138T1 (cg-RX-API-DMAC7.html)
IL (1) IL228561A (cg-RX-API-DMAC7.html)
JO (1) JO2958B1 (cg-RX-API-DMAC7.html)
MA (1) MA35014B1 (cg-RX-API-DMAC7.html)
ME (1) ME02021B (cg-RX-API-DMAC7.html)
MX (1) MX336057B (cg-RX-API-DMAC7.html)
MY (1) MY169452A (cg-RX-API-DMAC7.html)
PE (1) PE20141038A1 (cg-RX-API-DMAC7.html)
PH (1) PH12013502065A1 (cg-RX-API-DMAC7.html)
PL (1) PL2694508T3 (cg-RX-API-DMAC7.html)
PT (1) PT2694508E (cg-RX-API-DMAC7.html)
RS (1) RS53811B1 (cg-RX-API-DMAC7.html)
SG (1) SG193595A1 (cg-RX-API-DMAC7.html)
SI (1) SI2694508T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201500037B (cg-RX-API-DMAC7.html)
TN (1) TN2013000401A1 (cg-RX-API-DMAC7.html)
TW (2) TWI592158B (cg-RX-API-DMAC7.html)
UA (1) UA111604C2 (cg-RX-API-DMAC7.html)
UY (1) UY33985A (cg-RX-API-DMAC7.html)
WO (1) WO2012136553A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201307105B (cg-RX-API-DMAC7.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR064106A1 (es) 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
EP2168583A1 (en) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
JO3733B1 (ar) 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
EP2508525A1 (en) * 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
AP2015008750A0 (en) 2013-04-08 2015-09-30 Bayer Pharma AG Use of substituted 2,3-dihydroimidazo[1,2-c] quinazolines for treating lymphomas
KR20160019434A (ko) 2013-06-14 2016-02-19 바이엘 파마 악티엔게젤샤프트 항-tweakr 항체 및 그의 용도
CN103694319B (zh) * 2013-12-20 2018-02-27 深圳翰宇药业股份有限公司 一种布舍瑞林的纯化方法
EP3018131A1 (en) * 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
EP3018127A1 (en) * 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
WO2016142313A1 (en) * 2015-03-09 2016-09-15 Bayer Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
EA201791974A1 (ru) * 2015-03-09 2018-05-31 Байер Фарма Акциенгезельшафт Комбинации, содержащие замещенный 2,3-дигидроимидазо[1,2-с]хиназолин
JP6815329B2 (ja) 2015-03-23 2021-01-20 バイエル ファーマ アクチエンゲゼルシャフト 抗ceacam6抗体およびその使用
EP3824908A1 (en) 2015-04-10 2021-05-26 Capsugel Belgium NV Abiraterone acetate lipid formulations
TN2018000271A1 (en) 2016-02-01 2020-01-16 Bayer Pharma AG Copanlisib biomarkers.
TN2018000272A1 (en) 2016-02-01 2020-01-16 Bayer Pharma AG Copanlisib biomarkers
MY199595A (en) 2016-03-02 2023-11-08 Eisai R&D Man Co Ltd Eribulin-based antibody-drug conjugates and methods of use
WO2017153220A1 (en) 2016-03-08 2017-09-14 Bayer Pharma Aktiengesellschaft 2—amino—n— [7—methoxy—2, 3-dihydroimidazo-[1, 2-c] quinazolin-5-yl] pyrimidine—5—carboxamides
EP3219329A1 (en) 2016-03-17 2017-09-20 Bayer Pharma Aktiengesellschaft Combinations of copanlisib
WO2018054782A1 (en) 2016-09-23 2018-03-29 Bayer Pharma Aktiengesellschaft Combination of pi3k-inhibitors
AU2017376766A1 (en) 2016-12-14 2019-06-06 Tva (Abc), Llc HSP90-targeting conjugates and formulations thereof
CA3054249A1 (en) 2017-02-24 2018-08-30 Bayer Pharma Aktiengesellschaft Combinations of copanlisib with anti-pd-1 antibody
CA3068324A1 (en) 2017-06-28 2019-01-03 Bayer Consumer Care Ag Combination of a pi3k-inhibitor with an androgen receptor antagonist
EP3498266A1 (en) 2017-12-15 2019-06-19 Bayer Consumer Care AG Formulations of copanlisib
WO2019048527A1 (en) 2017-09-08 2019-03-14 Bayer Pharma Aktiengesellschaft COPANLISIB FORMULATIONS
WO2019105734A1 (en) 2017-11-28 2019-06-06 Bayer Consumer Care Ag Combinations of copanlisib
WO2019105835A1 (en) 2017-11-29 2019-06-06 Bayer Consumer Care Ag Combinations of copanlisib and anetumab ravtansine
WO2019197269A1 (en) 2018-04-11 2019-10-17 Bayer Aktiengesellschaft Combinations of copanlisib with triazolone derivatives and their use in the treatment of cancer
US20210187134A1 (en) 2018-08-28 2021-06-24 Bayer As Combination of pi3k-inhibitors and targeted thorium conjugates
EP3866805A1 (en) 2018-10-16 2021-08-25 Bayer Aktiengesellschaft Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compounds
JP2022505325A (ja) * 2018-10-17 2022-01-14 サンド・アクチエンゲゼルシヤフト レボチロキシン及びジカルボン酸を含む共結晶
US12139491B2 (en) * 2018-12-27 2024-11-12 Holosmedic Diketopiperazine derivatives as calcium ATPase inhibitor for enhancing anticancer activity
WO2020164997A1 (en) 2019-02-12 2020-08-20 Bayer Aktiengesellschaft Combination of pi3k-inhibitors
WO2023218032A1 (en) 2022-05-13 2023-11-16 Synthon B.V. Solid forms of copanlisib salts
WO2025053315A1 (ko) * 2023-09-08 2025-03-13 파로스젠 주식회사 항암제 프로드러그 컨쥬게이트의 제조에서 팔라듐의 회수 및 제거 방법

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH605550A5 (cg-RX-API-DMAC7.html) 1972-06-08 1978-09-29 Research Corp
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
TW225528B (cg-RX-API-DMAC7.html) 1992-04-03 1994-06-21 Ciba Geigy Ag
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
GB0021865D0 (en) 2000-09-06 2000-10-18 Smithkline Beecham Plc Novel pharmaceutical
WO2004029055A1 (en) * 2002-09-30 2004-04-08 Bayer Pharmaceuticals Corporation Fused azole-pyrimidine derivatives
JP4323793B2 (ja) 2002-12-16 2009-09-02 キヤノン株式会社 ズームレンズ及びそれを有する光学機器
AR064106A1 (es) * 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
CA2713388C (en) 2008-01-14 2016-03-29 William Scott Sulfone substituted 2,3-dihydroimidazo [1,2-c] quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
EP2168583A1 (en) * 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
EP2168582A1 (en) * 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Combinations of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
HUP0800765A2 (en) 2008-12-18 2010-11-29 Richter Gedeon Nyrt A new process for the preparation of piperazine derivatives and their hydrochloric salts
EA201201414A8 (ru) 2010-04-16 2013-12-30 Байер Интеллектчуал Проперти Гмбх КОМБИНАЦИИ, СОДЕРЖАЩИЕ ЗАМЕЩЕННЫЕ 2,3-ДИГИДРОИМИДАЗО[1,2-c]ХИНАЗОЛИНЫ
UA113280C2 (xx) 2010-11-11 2017-01-10 АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ
EP2508525A1 (en) * 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
JO3733B1 (ar) * 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
AP2015008750A0 (en) * 2013-04-08 2015-09-30 Bayer Pharma AG Use of substituted 2,3-dihydroimidazo[1,2-c] quinazolines for treating lymphomas
CN105934256B (zh) 2013-12-03 2019-12-27 拜耳制药股份公司 Pi3k-抑制剂的组合产品
EP3018127A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
EP3018131A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
WO2016142313A1 (en) * 2015-03-09 2016-09-15 Bayer Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
EA201791974A1 (ru) 2015-03-09 2018-05-31 Байер Фарма Акциенгезельшафт Комбинации, содержащие замещенный 2,3-дигидроимидазо[1,2-с]хиназолин

Also Published As

Publication number Publication date
ECSP13013006A (es) 2013-12-31
DOP2013000223A (es) 2013-11-15
SI2694508T1 (sl) 2015-03-31
EA023646B1 (ru) 2016-06-30
CN103649091B (zh) 2016-06-22
CY1116231T1 (el) 2017-02-08
JP5763834B2 (ja) 2015-08-12
US20160193219A1 (en) 2016-07-07
JO2958B1 (en) 2016-03-15
NZ616198A (en) 2015-09-25
UY33985A (es) 2012-10-31
TN2013000401A1 (en) 2015-03-30
CN103649091A (zh) 2014-03-19
TW201249847A (en) 2012-12-16
ME02021B (me) 2015-05-20
IL228561A (en) 2015-10-29
EA201391470A1 (ru) 2014-03-31
CR20130511A (es) 2013-12-04
MX336057B (es) 2016-01-07
CU20130133A7 (es) 2014-01-29
US20140072529A1 (en) 2014-03-13
EP2694508A1 (en) 2014-02-12
ES2529653T3 (es) 2015-02-24
CU24208B1 (es) 2016-11-29
PH12013502065A1 (en) 2016-06-29
TWI592158B (zh) 2017-07-21
CA2832123A1 (en) 2012-10-11
IL228561A0 (en) 2013-12-31
RS53811B1 (sr) 2015-06-30
WO2012136553A1 (en) 2012-10-11
EP2508525A1 (en) 2012-10-10
AU2012238891A1 (en) 2013-10-24
UA111604C2 (uk) 2016-05-25
MA35014B1 (fr) 2014-04-03
US9636344B2 (en) 2017-05-02
JP2015164936A (ja) 2015-09-17
HK1195907A1 (zh) 2014-11-28
AP3709A (en) 2016-05-31
US10383876B2 (en) 2019-08-20
KR101937501B1 (ko) 2019-01-10
TWI549954B (zh) 2016-09-21
DK2694508T3 (en) 2015-02-16
EP2694508B1 (en) 2014-11-19
CA2832123C (en) 2018-09-11
BR112013025549A2 (pt) 2016-12-27
SG193595A1 (en) 2013-10-30
PE20141038A1 (es) 2014-09-05
PT2694508E (pt) 2015-02-10
CL2013002870A1 (es) 2014-06-20
ZA201307105B (en) 2014-11-26
PL2694508T3 (pl) 2015-04-30
AP2013007219A0 (en) 2013-10-31
SMT201500037B (it) 2015-05-05
TW201637656A (zh) 2016-11-01
AU2012238891B2 (en) 2016-12-01
AR085718A1 (es) 2013-10-23
JP5826961B2 (ja) 2015-12-02
MY169452A (en) 2019-04-11
GT201300234A (es) 2015-01-16
CO6781534A2 (es) 2013-10-31
JP2014510119A (ja) 2014-04-24
KR20140021637A (ko) 2014-02-20
MX2013011583A (es) 2013-12-16

Similar Documents

Publication Publication Date Title
ES2948949T3 (es) Inhibidores de la interacción menina-MLL
US10344004B2 (en) Inhibitor of the mutated isocitrate dehydrogenase IDH1 R132H
EP3310775B1 (en) 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones
EP2802586B1 (en) Substituted imidazopyrazines as akt kinase inhibitors
US20210316017A1 (en) Pharmaceutical combination for the treatment of cancer
UA124474C2 (uk) БЕНЗІЗОТІАЗОЛЬНІ, ІЗОТІАЗОЛО[3,4-b]ПІРИДИНОВІ, ХІНАЗОЛІНОВІ, ФТАЛАЗИНОВІ, ПІРИДО[2,3-d]ПІРИДАЗИНОВІ Й ПІРИДО[2,3-d]ПІРИМІДИНОВІ ПОХІДНІ ЯК ІНГІБІТОРИ G12C KRAS ДЛЯ ЛІКУВАННЯ РАКУ ЛЕГЕНІ, РАКУ ПІДШЛУНКОВОЇ ЗАЛОЗИ АБО КОЛОРЕКТАЛЬНОГО РАКУ
EP3661517B1 (en) Dihydrooxadiazinones
EP3390387B1 (en) Heteroarylbenzimidazole compounds
WO2018153970A1 (en) Solid forms of 2-[(3r)-3-methylmorpholin-4-yl]-4-(1-methyl-1h-pyrazol-5-yl)-8-(1h-pyrazol-5-yl)-1,7-naphthyridine
WO2019002074A1 (en) THIAZOLE COMPOUNDS USEFUL AS INHIBITORS OF PRMT5
EP2807162B1 (de) Substituierte phenylimidazopyrazole und ihre verwendung
WO2018153969A1 (en) Combination of atr kinase inhibitors with radium-223 salt
TWI794288B (zh) 科帕利普(copanlisib)調配物
WO2018206547A1 (en) Combination of bub1 and atr inhibitors
WO2018153971A1 (en) Combination of atr kinase inhibitors
CA3008393A1 (en) Hetero-1,5,6,7-tetrahydro-4h-indol-4-ones
EP4249481A1 (en) Dihydroisoquinolinone and isoindolinone derivatives and uses thereof
EP2802588B1 (en) Substituted pyrazolopyrimidines as akt kinase inhibitors
JP2017071592A (ja) 癌幹細胞抑制剤、癌の転移又は再発の抑制剤並びに癌細胞の未分化マーカー発現抑制剤
EP3498266A1 (en) Formulations of copanlisib
EP3866805A1 (en) Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compounds
WO2015123174A1 (en) Pyrimidine imidazole amines as modulators of kinase activity
RU2851432C1 (ru) Соли (E)-4-(4-(диметиламино)стирил)-2-метилбензо[4,5]азоло[3,2-a]пиримидин-5-ия, обладающие цитотоксическим действием
TW202610626A (zh) HER2/mutEGFR抑制劑之結晶型式及製備彼等之方法
KR20260036930A (ko) 아미노피리미딘 유도체의 결정다형 및 이의 제조방법